Drugs / TG1050
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02428400 | Oct 2015 → Nov 2018 | chronic hepatitis B virus infection | Transgene | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2017-10-23 | Transgene | Results TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B transgene.com ↗
Transgene (Euronext Paris: TNG), a biotech company that designs and develops viral -based immunotherapies, announces that the analyses conducted on patients with chronic hepatitis B receiving standard antiviral therapies and a single dose of TG1050 in the Phase 1/1b trial, confirm the good tolerability profile and demonstrate the immunogenicity of th is novel therapeutic vaccine. |
| 2017-10-17 | Transgene | Results Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B transgene.com ↗
Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TG1050 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02428400 ↗ |
| Route | Subcutaneous | “administered SC as a single injection” NCT02428400 ↗ |